Beam Therapeutics Company Leadership
BEAM Stock | USD 27.37 0.17 0.63% |
Beam Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Beam Therapeutics suggests that most insiders are panicking. Beam Therapeutics employs about 472 people. The company is managed by 15 executives with a total tenure of roughly 1102 years, averaging almost 73.0 years of service per executive, having 31.47 employees per reported executive.
Beam Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-06 | Giuseppe Ciaramella | Disposed 51110 @ 26.36 | View | ||
2024-10-14 | Giuseppe Ciaramella | Disposed 51110 @ 26.27 | View | ||
2024-10-01 | Christine Bellon | Disposed 385 @ 23.48 | View | ||
2024-09-30 | John M Evans | Disposed 60000 @ 24.6 | View | ||
2024-07-01 | Amy Simon | Disposed 502 @ 23.76 | View | ||
2024-06-27 | John M Evans | Disposed 60000 @ 24.5 | View | ||
2024-04-01 | Terry-Ann Burrell | Disposed 5446 @ 32.12 | View | ||
2024-03-28 | John M Evans | Disposed 60000 @ 33.86 | View | ||
2024-02-13 | Fmr Llc | Disposed 1565 @ 30.76 | View | ||
2024-01-31 | John M Evans | Disposed 60000 @ 25.33 | View | ||
2024-01-03 | Christine Bellon | Disposed 1907 @ 26.42 | View |
Monitoring Beam Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Beam |
Beam Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Beam Therapeutics' future performance. Based on our forecasts, it is anticipated that Beam will maintain a workforce of about 470 employees by January 2025.Beam Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0928) % which means that it has lost $0.0928 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1829) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics' management efficiency ratios could be used to measure how well Beam Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Beam Therapeutics' Other Current Assets are very stable compared to the past year. As of the 1st of December 2024, Total Current Assets is likely to grow to about 1.3 B, while Non Current Assets Total are likely to drop about 193.3 M.As of the 1st of December 2024, Common Stock Shares Outstanding is likely to drop to about 56.2 M. In addition to that, Net Loss is likely to drop to about (245.9 M)
Beam Therapeutics Workforce Comparison
Beam Therapeutics is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 9,444. Beam Therapeutics holds roughly 472 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.41) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.46) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.46. Beam Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Beam Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Beam Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Beam Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.4286 | 3 | 7 | 41,754 | 144,648 |
2024-09-01 | 0.2222 | 2 | 9 | 7,500 | 144,292 |
2024-06-01 | 1.7143 | 12 | 7 | 369,782 | 115,170 |
2024-03-01 | 1.4286 | 10 | 7 | 585,000 | 1,023,472 |
2023-12-01 | 0.5 | 4 | 8 | 139,946 | 144,285 |
2023-09-01 | 0.5 | 3 | 6 | 92,490 | 249,411 |
2023-06-01 | 0.4545 | 5 | 11 | 82,660 | 38,157 |
2023-03-01 | 0.7241 | 21 | 29 | 520,371 | 619,540 |
2022-12-01 | 0.2 | 3 | 15 | 31,363 | 150,589 |
2022-09-01 | 2.0 | 16 | 8 | 1,003,425 | 1,400,029 |
2022-06-01 | 0.4444 | 4 | 9 | 1,084,861 | 1,652,383 |
2022-03-01 | 0.4375 | 7 | 16 | 358,750 | 159,907 |
2021-12-01 | 0.3 | 6 | 20 | 112,533 | 191,100 |
2021-09-01 | 0.4043 | 19 | 47 | 5,480,233 | 9,132,804 |
2021-06-01 | 0.6458 | 31 | 48 | 248,648 | 3,562,250 |
2021-03-01 | 0.9259 | 25 | 27 | 763,218 | 3,654,030 |
2020-12-01 | 0.0952 | 2 | 21 | 55,842 | 121,984 |
2020-09-01 | 1.5 | 3 | 2 | 367,714 | 11,040 |
2020-06-01 | 1.0 | 1 | 1 | 115,000 | 115,000 |
2020-03-01 | 0.6552 | 19 | 29 | 34,793,667 | 55,823,725 |
Beam Therapeutics Notable Stakeholders
A Beam Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Beam Therapeutics often face trade-offs trying to please all of them. Beam Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Beam Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dr JD | Chief VP | Profile | |
Manmohan Singh | Chief Officer | Profile | |
Nicole Gaudelli | CoFounder | Profile | |
Brian Riley | VP Operations | Profile | |
Susan OConnor | Chief Officer | Profile | |
Alexis Komor | CoFounder | Profile | |
Amy MD | Chief Officer | Profile | |
Suzanne Fleming | Chief Officer | Profile | |
TerryAnn MBA | CFO Treasurer | Profile | |
Giuseppe Ciaramella | Pres Officer | Profile | |
David Liu | CoFounder | Profile | |
Feng Zhang | CoFounder | Profile | |
John MBA | CEO Director | Profile | |
Bethany Cavanagh | Senior Treasurer | Profile | |
Gopi Shanker | Chief Officer | Profile |
About Beam Therapeutics Management Performance
The success or failure of an entity such as Beam Therapeutics often depends on how effective the management is. Beam Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Beam management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Beam management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.09) | (0.10) | |
Return On Capital Employed | (0.14) | (0.13) | |
Return On Assets | (0.09) | (0.10) | |
Return On Equity | (0.14) | (0.14) |
Beam Therapeutics Workforce Analysis
Traditionally, organizations such as Beam Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Beam Therapeutics within its industry.Beam Therapeutics Manpower Efficiency
Return on Beam Therapeutics Manpower
Revenue Per Employee | 800.2K | |
Revenue Per Executive | 25.2M | |
Net Loss Per Employee | 280.8K | |
Net Loss Per Executive | 8.8M | |
Working Capital Per Employee | 2.1M | |
Working Capital Per Executive | 67M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.